Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Dr Lal PathLabs Ltd (DLPL IN)
Watchlist
Contact IR
78
Analysis
Health Care
•
India
Dr. Lal PathLabs Limited operates clinical laboratories. The Company offers medical diagnostic, cardiology, radiology, pathology and imaging, health checkup, blood test, and customer care services. Dr. Lal PathLabs conducts its business in India.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
SBFC Finance Limited
•
07 Nov 2023 12:08
[Week 10] Namaste India 🙏 | Earnings Edition - Final Part
This Insight is the final dedicated earnings edition, providing a consolidated view of all earnings tracked so far. At the end we also provide...
Pranav Bhavsar
Follow
347 Views
Share
bullish
•
Agilus Diagnostics Limited
•
17 Oct 2023 15:39
Agilus Diagnostics Pre-IPO: Large Scale of Operation and Favorable Sector Demand To Drive Growth
Agilus Diagnostics is the largest diagnostics service provider in India. With pan-India network and comprehensive test menu, the company is poised...
Tina Banerjee
Follow
721 Views
Share
bullish
•
Prodia
•
30 Sep 2023 13:23
Prodia (PRDA IJ) - Going Digital with Precision
Prodia (PRDA IJ) remains one of our top healthcare picks in Indonesia, with rising health consciousness driving higher demand for testing....
Angus Mackintosh
Follow
749 Views
Share
bearish
•
EURO STOXX 50 Price EUR
•
29 Sep 2023 16:05
Supports Starting to Break; Upgrading Non-U.S. Small-Caps to Overweight; Transports/Comm/HC Buys
Support levels on global indexes (EURO STOXX 50, $ACWX, $EFA) beginning to break as $DXY and 10-year Treasury yield $TNX break above $105.70 and...
Vermilion Research
Follow
569 Views
Share
bullish
•
Dr Lal PathLabs Ltd
•
11 Jul 2023 14:05
Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook
Dr Lal PathLabs reported 14% and 16%, YoY, non-COVID revenue growth in 4QFY23 and FY23, respectively. Due to lesser competitive threat and recent...
Tina Banerjee
Follow
299 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x